- PR Newswire•2 days agoComprehensive Economic Analysis Published in Reviews in Urology Demonstrates Oncotype DX® Prostate Cancer Test Leads to Substantial Cost Savings and Increase in Active Surveillance
"Not all low-risk prostate cancers are aggressive, but it is critical to know exactly which patient can forego immediate surgery safely," said study principal investigator David M. Albala, M.D., chief of urology, Crouse Hospital, Syracuse, New York. "Better treatment decisions can be made when patients have genomic information about their prostate tumors. Led by Associated Medical Professionals (AMP) of New York, the study demonstrated that incorporation of the GPS as part of the treatment decision algorithm for prostate cancer patients with NCCN very low and low-risk disease (64 percent of the study population) led to a 21 percent net increase in the use of active surveillance.
- PR Newswire•3 days agoGenomic Health to Announce Third Quarter 2016 Financial Results and Host Conference Call on Tuesday, November 1, 2016
REDWOOD CITY, Calif., Oct. 25, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, November 1 at 4:30 p.m. Eastern ...
- StreetAuthority Network•15 days ago
Nestled within the beauty of Maine's Acadia National Park, on the picturesque Mount Desert Island, is a place known to many scientists and health care investors as the place where the term "
Genomic Health Inc. (GHDX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||29.69 x 100|
|Ask||29.76 x 100|
|Day's Range||29.08 - 29.92|
|52wk Range||20.54 - 35.79|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-36.07|
|Avg Vol (3m)||218,841|
|Dividend & Yield||N/A (N/A)|